By Iain Gilbert
Date: Monday 15 Sep 2025
(Sharecast News) - Medical diagnostics firm Renalytix said on Monday that it has struck a definitive agreement with Tempus AI to accelerate the adoption of its kidneyintelX.dkd test to support early-stage risk assessment in chronic kidney disease, slow progression, and improve patient outcomes.
By Josh White
Date: Tuesday 03 Jun 2025
(Sharecast News) - Renalytix announced a new collaboration with New York Kidney & Hypertension Medicine (NYKHM) on Tuesday, aimed at expanding access to its FDA-approved kidneyintelX.dkd test across underserved communities in the Greater New York area.
By Iain Gilbert
Date: Thursday 10 Apr 2025
(Sharecast News) - Precision medicine business Renalytix said on Thursday that Q3 trading was in line with expectations, delivering 20% quarter-on-quarter revenue growth as it reached "the key milestone" of processing over 1,000 billable tests within the quarter for the first time.
Currency | UK Pounds |
Share Price | 8.67p |
Change Today | -0.31p |
% Change | -3.49 % |
52 Week High | 12.50 |
52 Week Low | 5.62 |
Volume | 7,582,698 |
Shares Issued | 189.93m |
Market Cap | £16.46m |
RiskGrade | 348 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
10:54 | 117,826 @ 8.90p |
10:53 | 26,404 @ 8.90p |
10:48 | 28,874 @ 8.78p |
10:44 | 4,500 @ 8.93p |
10:44 | 222 @ 9.00p |
You are here: research